These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 25743816

  • 21. Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma.
    Zhu HT, Ai DS, Tang HR, Badakhshi H, Fan JH, Deng JY, Zhang JH, Chen Y, Zhang Z, Xia Y, Guo XM, Jiang GL, Zhao KL.
    World J Gastroenterol; 2017 Jan 21; 23(3):540-546. PubMed ID: 28210091
    [Abstract] [Full Text] [Related]

  • 22. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.
    Shridhar R, Freilich J, Hoffe SE, Almhanna K, Fulp WJ, Yue B, Karl RC, Meredith K.
    Ann Surg Oncol; 2014 Nov 21; 21(12):3744-50. PubMed ID: 24854492
    [Abstract] [Full Text] [Related]

  • 23. Comparative study of radiotherapy plus erlotinib versus chemoradiotherapy for elderly patients with esophageal cancer: a propensity score-matched analysis.
    Song T, Du D, Zhang X, Fang M, Wu S.
    Dis Esophagus; 2017 Sep 01; 30(9):1-10. PubMed ID: 28859362
    [Abstract] [Full Text] [Related]

  • 24. Three-dimensional conformal radiotherapy with concurrent chemotherapy for postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy and failure pattern.
    Bao Y, Liu S, Zhou Q, Cai P, Anfossi S, Li Q, Hu Y, Liu M, Fu J, Rong T, Li Q, Liu H.
    Radiat Oncol; 2013 Oct 18; 8():241. PubMed ID: 24139225
    [Abstract] [Full Text] [Related]

  • 25. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
    Hu G, Wang Z, Wang Y, Zhang Q, Tang N, Guo J, Liu L, Han X.
    Drug Des Devel Ther; 2016 Oct 18; 10():2129-36. PubMed ID: 27445460
    [Abstract] [Full Text] [Related]

  • 26. Baseline nutritional status is prognostic factor after definitive radiochemotherapy for esophageal cancer.
    Clavier JB, Antoni D, Atlani D, Ben Abdelghani M, Schumacher C, Dufour P, Kurtz JE, Noel G.
    Dis Esophagus; 2014 Aug 18; 27(6):560-7. PubMed ID: 23106980
    [Abstract] [Full Text] [Related]

  • 27. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
    Wang W, Hou X, Yan J, Shen J, Lian X, Sun S, Liu Z, Meng Q, Wang D, Zhao M, Qiu J, Hu K, Zhang F.
    BMC Cancer; 2017 Aug 01; 17(1):510. PubMed ID: 28764676
    [Abstract] [Full Text] [Related]

  • 28. Cardiac radiation dose predicts survival in esophageal squamous cell carcinoma treated by definitive concurrent chemotherapy and intensity modulated radiotherapy.
    Pao TH, Chang WL, Chiang NJ, Chang JS, Lin CY, Lai WW, Tseng YL, Yen YT, Chung TJ, Lin FC.
    Radiat Oncol; 2020 Sep 22; 15(1):221. PubMed ID: 32962730
    [Abstract] [Full Text] [Related]

  • 29. Clinical Effect of Radiotherapy Combined with Chemotherapy for Non-Surgical Treatment of the Esophageal Squamous Cell Carcinoma.
    Chen H, Zhou L, Yang Y, Yang L, Chen L.
    Med Sci Monit; 2018 Jun 19; 24():4183-4191. PubMed ID: 29915168
    [Abstract] [Full Text] [Related]

  • 30. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
    Sanford NN, Catalano PJ, Enzinger PC, King BL, Bueno R, Martin NE, Hong TS, Wo JY, Mamon HJ.
    Dis Esophagus; 2017 Jul 01; 30(7):1-8. PubMed ID: 28475728
    [Abstract] [Full Text] [Related]

  • 31. Comparison of definitive chemoradiotherapy and radiotherapy alone in patients older than 75 years with locally advanced esophageal carcinoma: A retrospective cohort study.
    Zhao Q, Hu G, Xiao W, Chen Y, Shen M, Tang Q, Ning X.
    Medicine (Baltimore); 2017 Sep 01; 96(35):e7920. PubMed ID: 28858114
    [Abstract] [Full Text] [Related]

  • 32. Prognostic impact of the 6th and 7th American Joint Committee on Cancer TNM staging systems on esophageal cancer patients treated with chemoradiotherapy.
    Nomura M, Shitara K, Kodaira T, Hatooka S, Mizota A, Kondoh C, Yokota T, Takahari D, Ura T, Muro K.
    Int J Radiat Oncol Biol Phys; 2012 Feb 01; 82(2):946-52. PubMed ID: 21362578
    [Abstract] [Full Text] [Related]

  • 33. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
    Yang KL, Chang YC, Ko HL, Chi MS, Wang HE, Hsu PS, Lin CC, Yeh DY, Kao SJ, Jiang JS, Chi KH.
    Clin Lung Cancer; 2016 Nov 01; 17(6):550-557. PubMed ID: 27378175
    [Abstract] [Full Text] [Related]

  • 34. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
    Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N, Takiuchi H, Komatsu Y, Miyata Y, Fukuda H, Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group (JCOG).
    Int J Radiat Oncol Biol Phys; 2011 Nov 01; 81(3):684-90. PubMed ID: 20932658
    [Abstract] [Full Text] [Related]

  • 35. Prognostic significance of CYFRA21-1, CEA and hemoglobin in patients with esophageal squamous cancer undergoing concurrent chemoradiotherapy.
    Zhang HQ, Wang RB, Yan HJ, Zhao W, Zhu KL, Jiang SM, Hu XG, Yu JM.
    Asian Pac J Cancer Prev; 2012 Nov 01; 13(1):199-203. PubMed ID: 22502668
    [Abstract] [Full Text] [Related]

  • 36. Concurrent cisplatin and 5-fluorouracil versus concurrent cisplatin and docetaxel with radiotherapy for esophageal squamous cell carcinoma: a propensity score-matched analysis.
    Zhang P, Xi M, Li QQ, Hu YH, Guo X, Zhao L, Liu H, Liu SL, Luo LL, Liu Q, Liu MZ.
    Oncotarget; 2016 Jul 12; 7(28):44686-44694. PubMed ID: 27183916
    [Abstract] [Full Text] [Related]

  • 37. Palliative radiotherapy and chemoradiotherapy in stage IVA/B esophageal cancer patients with dysphagia.
    Kawamoto T, Nihei K, Sasai K, Karasawa K.
    Int J Clin Oncol; 2018 Dec 12; 23(6):1076-1083. PubMed ID: 30066207
    [Abstract] [Full Text] [Related]

  • 38. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
    Koo DH, Park SI, Kim YH, Kim JH, Jung HY, Lee GH, Choi KD, Song HJ, Song HY, Shin JH, Cho KJ, Yoon DH, Kim SB.
    Cancer Chemother Pharmacol; 2012 Mar 12; 69(3):655-63. PubMed ID: 21968953
    [Abstract] [Full Text] [Related]

  • 39. Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma.
    Hashimoto J, Kato K, Ito Y, Kojima T, Akimoto T, Daiko H, Hamamoto Y, Matsushita H, Katano S, Hara H, Tanaka Y, Saito Y, Nagashima K, Igaki H.
    Int J Clin Oncol; 2019 Jan 12; 24(1):60-67. PubMed ID: 30109544
    [Abstract] [Full Text] [Related]

  • 40. Feasibility and efficiency of concurrent chemoradiotherapy with capecitabine and cisplatin versus radiotherapy alone for elderly patients with locally advanced esophageal squamous cell carcinoma: Experience of two centers.
    Chen F, Luo H, Xing L, Liang N, Xie J, Zhang J.
    Thorac Cancer; 2018 Jan 12; 9(1):59-65. PubMed ID: 29024498
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.